Enspryng won FDA approval on Oct 15, 2026, for adults with thyroid eye disease, giving patients the first treatment for the condition they can take at home. Genentech, the Roche subsidiary behind the drug, announced the clearance after two Phase 3 trials showed the medicine outperformed a placebo on the disease’s most visible symptoms.
Thyroid eye disease is an autoimmune condition in which the immune system attacks the tissues around the eyes. Patients can develop bulging eyes, double vision, eye pain and swelling, and in severe cases the disease threatens sight. Until now, treatment options required visits to a clinic or infusion center.
Enspryng, known generically as satralizumab-mwge, is given as a subcutaneous injection that patients or trained caregivers can administer themselves. That makes it the first and only at-home treatment option for thyroid eye disease, removing the travel and scheduling burden of clinic-based therapy.
The drug is an interleukin-6 receptor inhibitor. It blocks the inflammatory signaling that drives the tissue damage in thyroid eye disease, calming the immune attack on the muscles and fat behind the eyes.
The SatraGO trials behind Enspryng
Approval rested on two Phase 3 studies, SatraGO-1 and SatraGO-2, which together enrolled 258 patients across 19 countries. Both compared Enspryng against a placebo in adults with active thyroid eye disease.
In SatraGO-2, the proptosis response, meaning a meaningful reduction in how far the eye bulges, reached 52.9 percent with Enspryng versus 23.4 percent with placebo. Double vision improved in 60.7 percent of patients on the drug compared with 25.8 percent on placebo.
Those are the two outcomes patients notice most. Proptosis changes how a person looks and can prevent the eyelids from closing fully, which dries and damages the eye surface. Double vision makes driving, reading and working difficult. Improvements on both measures were the core of the case for approval.
No new safety signals emerged across the SatraGO studies. Because Enspryng was already approved for another condition, regulators and doctors had years of safety data to weigh alongside the new trial results.
How at-home Enspryng treatment works
Enspryng is injected under the skin, a route patients can learn in a single training session. The drug’s maker says patients or trained caregivers can handle the injections, which means most doses happen at home rather than in a clinic.
The schedule matters to patients planning around the therapy. After initial doses, injections are spaced weeks apart, a rhythm designed to keep the interleukin-6 blockade steady without frequent trips to a doctor’s office.
Doctors will still monitor patients during treatment. Thyroid eye disease can flare, and the underlying thyroid condition that usually accompanies it needs its own management. But the monitoring visits are separate from the act of taking the medicine, which is the shift this approval represents.
For people in rural areas or far from specialty eye centers, the at-home option removes a practical barrier. Clinic-based treatments for thyroid eye disease often require repeated long trips, and missing doses can blunt the benefit.
What the approval means for patients
The clearance expands Enspryng beyond neuromyelitis optica spectrum disorder, the rare neurological condition it was first approved to treat. The drug’s safety record in that population gave regulators confidence in extending its use to the eye disease.
Thyroid eye disease most often strikes people with Graves’ disease, an overactive-thyroid condition, though it can appear in people with normal thyroid function. The disease typically runs an active phase of worsening symptoms followed by a stable phase, and treatment during the active phase aims to limit permanent damage.
Genentech has not announced pricing for the new use. Coverage decisions by insurers will shape how quickly patients can actually get the drug, and prior authorization is likely given the price of specialty biologics.
The company said the drug will be available through specialty pharmacies. Patients starting the treatment should expect training on the injection technique and a monitoring plan from their prescribing doctor as the rollout begins.